[go: up one dir, main page]

GT200100037A - Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina. - Google Patents

Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.

Info

Publication number
GT200100037A
GT200100037A GT200100037A GT200100037A GT200100037A GT 200100037 A GT200100037 A GT 200100037A GT 200100037 A GT200100037 A GT 200100037A GT 200100037 A GT200100037 A GT 200100037A GT 200100037 A GT200100037 A GT 200100037A
Authority
GT
Guatemala
Prior art keywords
cycline
inhibitors
depends
alquilpirido
pyrimidins
Prior art date
Application number
GT200100037A
Other languages
English (en)
Spanish (es)
Inventor
Booth Richard John
Dobrusin Ellen Myra
Toogood Peter Laurence
Vaderwel Scott Norman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100037A publication Critical patent/GT200100037A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GT200100037A 2000-03-06 2001-03-05 Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina. GT200100037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
GT200100037A true GT200100037A (es) 2002-03-04

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100037A GT200100037A (es) 2000-03-06 2001-03-05 Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.

Country Status (36)

Country Link
EP (1) EP1268476A1 (xx)
JP (1) JP2003528101A (xx)
KR (1) KR20020075805A (xx)
CN (1) CN1422268A (xx)
AP (1) AP2002002643A0 (xx)
AR (1) AR034119A1 (xx)
AU (1) AU2001233028A1 (xx)
BG (1) BG107161A (xx)
BR (1) BR0109056A (xx)
CA (1) CA2401368A1 (xx)
CO (1) CO5280200A1 (xx)
CR (1) CR6736A (xx)
CZ (1) CZ20022929A3 (xx)
DZ (1) DZ3308A1 (xx)
EA (1) EA200200802A1 (xx)
EE (1) EE200200506A (xx)
GT (1) GT200100037A (xx)
HN (1) HN2001000040A (xx)
HR (1) HRP20020798A2 (xx)
HU (1) HUP0300136A2 (xx)
IL (1) IL151480A0 (xx)
IS (1) IS6524A (xx)
MA (1) MA26881A1 (xx)
MX (1) MXPA02008535A (xx)
NO (1) NO20024235L (xx)
NZ (1) NZ520962A (xx)
OA (1) OA12227A (xx)
PA (1) PA8513201A1 (xx)
PE (1) PE20011177A1 (xx)
PL (1) PL358271A1 (xx)
SK (1) SK12472002A3 (xx)
SV (1) SV2001000338A (xx)
TN (1) TNSN01036A1 (xx)
WO (1) WO2001070741A1 (xx)
YU (1) YU66502A (xx)
ZA (1) ZA200207110B (xx)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
KR100639772B1 (ko) * 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
CA2473026C (en) 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
ATE370952T1 (de) 2002-04-19 2007-09-15 Smithkline Beecham Corp Neue verbindungen
WO2004011456A1 (en) 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
JP4616839B2 (ja) 2003-11-13 2011-01-19 エフ．ホフマン−ラ ロシュ アーゲー ヒドロキシアルキル置換ピリド−７−ピリミジン−７−オン類
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2008527007A (ja) 2005-01-14 2008-07-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｒａｆ−キナーゼ阻害活性を有するシンナミドおよびヒドロシンナミド誘導体
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
WO2006104917A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CA2623770C (en) * 2005-10-07 2014-05-27 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
ES2366489T3 (es) 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
CA2682981C (en) * 2007-04-03 2015-11-17 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
NZ581936A (en) * 2007-06-15 2011-08-26 Msd Kk Bicycloaniline derivatives
EP3098223A1 (en) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
CA2709202C (en) 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
CA2719538C (en) * 2008-04-07 2014-03-18 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011044535A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
EP2512250A4 (en) * 2009-12-18 2013-06-05 Univ Temple SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONE AND THERAPEUTIC USES THEREOF
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
DK2600719T3 (da) * 2010-08-05 2014-12-15 Univ Temple 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EA025496B1 (ru) * 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
WO2014128588A1 (en) * 2013-02-21 2014-08-28 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
EP3497103B1 (en) 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
JP7226804B2 (ja) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド Ｆｇｆｒキナーゼ阻害剤及び医薬用途
KR20200131246A (ko) 2018-02-15 2020-11-23 누베이션 바이오 인크. 키나제 억제제로서의 헤테로시클릭 화합물
TW202035406A (zh) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 作為cdk-hdac雙通路抑制劑的雜環化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN115348963B (zh) * 2021-03-08 2024-04-19 暨南大学 吡啶并嘧啶类化合物及其应用
WO2024056091A1 (zh) * 2022-09-16 2024-03-21 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AU749750B2 (en) * 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung

Also Published As

Publication number Publication date
JP2003528101A (ja) 2003-09-24
NO20024235D0 (no) 2002-09-05
PA8513201A1 (es) 2003-06-30
EA200200802A1 (ru) 2003-02-27
CO5280200A1 (es) 2003-05-30
HN2001000040A (es) 2001-09-06
HRP20020798A2 (en) 2004-02-29
DZ3308A1 (fr) 2001-09-27
SV2001000338A (es) 2001-11-30
SK12472002A3 (sk) 2003-04-01
PE20011177A1 (es) 2001-11-23
CN1422268A (zh) 2003-06-04
KR20020075805A (ko) 2002-10-05
HUP0300136A2 (en) 2003-05-28
EP1268476A1 (en) 2003-01-02
AR034119A1 (es) 2004-02-04
OA12227A (en) 2004-03-18
WO2001070741A1 (en) 2001-09-27
MXPA02008535A (es) 2002-12-13
PL358271A1 (en) 2004-08-09
NZ520962A (en) 2003-09-26
EE200200506A (et) 2004-02-16
IS6524A (is) 2002-08-23
ZA200207110B (en) 2003-12-04
CR6736A (es) 2004-03-10
YU66502A (sh) 2005-09-19
MA26881A1 (fr) 2004-12-20
IL151480A0 (en) 2003-04-10
BR0109056A (pt) 2003-06-03
NO20024235L (no) 2002-11-05
TNSN01036A1 (en) 2005-11-10
BG107161A (en) 2003-06-30
AU2001233028A1 (en) 2001-10-03
AP2002002643A0 (en) 2002-12-31
CA2401368A1 (en) 2001-09-27
CZ20022929A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
GT200100037A (es) Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
SV2004001459A (es) 2- (piridin-2-ilamino) -pirido [2,3-d]pirimidin-7-onas ref. pc20501
CO4340688A1 (es) Derivados de quinazolina y procedimientos de uso de los mismos, como agentes contra el cancer, en los mamiferos.
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
PA8537501A1 (es) Naftostirilos
ES2174250T3 (es) Inhibidores irreversibles de las quinasas de tirosina.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
SV2003001493A (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
SV2002000602A (es) Compuestos farmaceuticos ref.pcs10 398ajer/bb
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
CR10370A (es) Derivados sustituidos de pirrolo-pirazol inhibidores de quinasa (divisional exp. 7880)
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
PA8598801A1 (es) Sales de los inhibidores triciclicos de las poli (adp-ribosa) polimerasas
AR010348A1 (es) Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR037109A1 (es) Uso de flibanserina
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
AR032293A1 (es) Estuche farmaceutico
CR8546A (es) DERIVADOS DE 1H-TIENO [2,3c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA